Healthcare Realty (HR) Q1 2026 earnings review
Transformation Complete: Operational Engine Accelerates While Balance Sheet Stabilizes
Healthcare Realty's '2.0' strategic turnaround is visibly working. After a painful 2025 defined by a dividend cut and $1.2B in asset dispositions, the company has successfully pivoted from defense to offense. Q1 2026 results showed remarkable underlying operational strength: Same Store Cash NOI growth surged to an accelerating 6.9%, driven by an exceptional 93.5% tenant retention rate and 4.2% cash leasing spreads. While total revenue contracted 6.7% YoY to $279M—an expected outcome of last year's heavy disposition program—underlying Normalized FFO rose to $0.41 per share. Leverage is stable at 5.5x, giving management the confidence to deploy $100M into share repurchases and raise full-year guidance.
🐂 Bull Case
The operational metrics are outstanding. A 93.5% tenant retention rate completely minimizes downtime and capital expenditures, allowing 4.2% cash leasing spreads to flow directly to the bottom line.
With the balance sheet fixed (5.5x leverage), HR shifted to offense. The repurchase of 5.7M shares at an average of $17.38 demonstrates management's commitment to utilizing newly created liquidity for highly accretive, immediate FFO growth.
🐻 Bear Case
The company has $600M in 3.5% senior notes maturing in August 2026. Refinancing this tranche at current market rates will create an unavoidable interest expense drag on FFO.
The necessary medicine of the 2025 disposition program means total revenue is down roughly 7% YoY. Absolute dollar scale is smaller, putting more pressure on organic growth and redevelopment to drive total earnings.
⚖️ Verdict: 🟢
Bullish. The tough strategic choices made in 2025 are paying off. The core portfolio is delivering sector-leading organic growth, and management is executing capital allocation flawlessly by buying back discounted shares.
Key Themes
Same Store NOI Growth is Accelerating Rapidly
The most compelling metric in the print is the 6.9% Same Store Cash NOI growth. This represents a continuous acceleration from 2.3% a year ago. It was driven by a powerful combination of 4.2% cash leasing spreads on 1.7M sq ft of renewals and a staggering 93.5% tenant retention rate. High retention is the holy grail for MOB REITs—it eliminates vacancy downtime and severely limits second-generation tenant improvement costs.
Share Repurchases Signal Balance Sheet Confidence
After spending 2025 aggressively selling assets to pay down debt, HR shifted its capital allocation strategy. In Q1, the company repurchased 5.7M shares for $100M at an average price of $17.38. With leverage resting comfortably at 5.5x (down from 6.4x a year ago), utilizing free cash flow and disposition proceeds for buybacks at a discount to NAV provides immediate FFO accretion.
The Q3 2026 Maturity Wall Looms
While leverage metrics are healthy, HR faces a notable refinancing hurdle: $600M of Senior Notes carrying a low 3.50% coupon mature in August 2026. Management has pre-positioned liquidity (via a new $400M delayed draw term loan and a $600M commercial paper program), but refinancing this debt at higher current rates (management previously guided to the 'low 5%' area) will act as a structural headwind to earnings growth in late 2026.
Absolute Revenue Contraction
Total revenue dropped to $278.9M from $298.9M a year ago. This is a decelerating trend caused by the strategic shedding of ~$1.2B in assets throughout 2025. While same-store metrics are fantastic, the outright contraction of the revenue base means fixed corporate costs must be spread over a smaller asset footprint, making G&A cost control critical.
Redevelopment Pipeline Funding Future Upside
Internal reinvestment remains the primary growth driver outside of escalators. In Q1, HR added two new redevelopment projects ($31M budget), completed one, and commenced a major 155,000 sq ft redevelopment at Tufts Medical Center in Boston. The transition of the 'Lease-Up' portfolio via these redevelopment projects remains vital for HR to achieve its 3-year NOI target.
Other KPIs
Stable compared to 5.4x in 25Q4, and a massive improvement from 6.4x in 25Q1. This confirms that the severe deleveraging phase of the 'Healthcare Realty 2.0' plan is complete, keeping the company squarely within its targeted mid-5x range.
Stable. Compares favorably to $0.39 a year ago and $0.40 in 25Q4. Reaching $0.41 despite the dilutive impact of 2025's massive asset disposition program proves that core operational improvements are successfully offsetting the loss of disposed NOI.
Guidance
Accelerating vs prior guidance. Management raised the range by 25bps from the previous 3.5%-4.5%. However, compared to Q1's actual print of 6.9%, the guidance implies a deceleration through the rest of the year, likely reflecting conservatism regarding the sustainability of a 93.5% retention rate.
Accelerating slightly. The midpoint of $1.62 represents a $0.01 bump from previous guidance. This suggests stable, modest growth over FY25's $1.61 actual, underscoring that the core portfolio's strength is outpacing the dilution from asset sales.
Stable. Unchanged from prior guidance. The GAAP net loss figures remain depressed by non-cash real estate depreciation and amortization ($128.9M in Q1 alone), which is standard for the REIT sector.
Key Questions
Refinancing Strategy for August Maturities
You have a new $400M delayed draw term loan and $600M of commercial paper capacity. How exactly do you plan to structure the refinancing of the $600M in 3.5% senior notes maturing in August, and what is your updated assumption for the new blended interest rate?
Sustainability of Retention Rates
Tenant retention hit an incredibly high 93.5% this quarter. Is this a structural new normal reflecting the revamped asset management platform, or a quarterly anomaly? What retention rate is baked into the rest of the 2026 Same Store NOI guidance?
Capital Allocation Hierarchy
Having executed $100M in share repurchases at $17.38, how are you currently measuring the hurdle rate for further buybacks versus deploying capital into Joint Venture acquisitions or expanding the redevelopment pipeline?